This author has yet to write their bio.
Meanwhile lets just say that we are proud chen, chenyan contributed a whooping 385 entries.
On August 30, 2020, “the 37th?China Pharmaceutical Industry Information Annual Conference2020” hosted by China Pharmaceutical Industry Information Center was held in Zhuhai, Guangdong Province, and the conference released the list of the Top 100 Pharmaceutical Enterprises in China in 2019, which attracted much attention from the industry.
Sahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has launched Sahne??Medical Spray and Sahne??Medical Cream (both are category-2 OTC drugs, “Sahne Medical”) on August 25, 2020 at pharmacies and drugstores throughout Japan, as a new product of the Sahne brand lineup which has been a favored hand care for generations.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a total of 10 presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGOTM CIV) will be given at the 34th annual meeting of the Associated Professional Sleep Societies (SLEEP 2020), to be held virtually from August 27 to 30, 2020.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, President: Jannie Oothuizen, “MSD”), a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that Eisai has submitted an application in Japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor LENVIMA???(generic name: lenvatinib mesylate). In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and DeNA Co., Ltd.’s subsidiary DeSC Healthcare Co., Ltd. (Headquarters: Tokyo, CEO: Sho Segawa, CMO: Kuniaki Miyake, “DeNA”) announced that they have begun provision of the brain performance application “Easiit” (non-medical device, referred to below as “Easiit App”), for preparation against dementia, on July 28, 2020.
Allm Inc. (Shibuya-ku, Tokyo, President: Teppei Sakano, hereafter Allm), Tokyo Medical and Dental University (Bunkyo-ku, Tokyo, President: Yujiro Tanaka) and Eisai Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, CEO: Haruo Naito, hereafter Eisai) announced that their jointly submitted study and development project has been selected by the Japan Agency for Medical Research and Development (AMED) for its publicly advertised 2020 “Field of Support for Experimental Study on Medical Devices and Systems that Contribute to Measures Against Viruses and Other Infectious Diseases” as part of its “Technology Development Project for Measures against Viruses and Other Infectious Diseases “, and that Allm has entered into an industry-academia-government joint research agreement with Tokyo Medical and Dental University and Eisai respectively.
The Alzheimer’s Clinical Trials Consortium (ACTC), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that a new Phase III clinical study (AHEAD 3-45) of BAN2401, an anti-amyloid beta (Aβ) protofibril antibody, has been initiated in the United States of America for individuals with preclinical Alzheimer’s disease (AD), meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the “Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment”, which is a research project with Eisai as the representative research organization. This joint research project was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program. In this project, Eisai aims at creating a Japan-originated therapeutic drug for systemic lupus erythematosus (SLE) through industry-academia-government collaboration, using its in-house discovered new oral Toll-Like Receptor (TLR) 7/8 inhibitor E6742.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa??(perampanel hydrate) in Japan on July 6, 2020. Eisai received marketing and manufacturing approval for this formulation on January 23, 2020, and the fine granule formulation was added to Japan’s National Health Insurance drug price list on April 23 of the same year.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that Eisai Korea Inc., Eisai’s subsidiary in South Korea, has received marketing approval of Parkinson’s disease treatment Equfina??(safinamide mesilate, “safinamide”) for the indication of treatment of idiopathic Parkinson’s disease as adjunctive therapy with levodopa-containing products in patients with end of dose motor fluctuations from the regulatory authority in South Korea (Ministry of Food and Drug Safety).
Copyright(c) 2011 Eisai China lnc.All Rights Reserved.
滬ICP備11005394號-1
滬公網安備31010602001439號
021-62881220
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy